Gemcitabine (Gemtaza) Dosing and Management
For pancreatic cancer, use gemcitabine 1000 mg/m² IV over 30 minutes weekly for 7 weeks, then after 1 week rest, continue weekly on days 1,8, and 15 of each 28-day cycle. 1
Dosing Schedules by Cancer Type
Pancreatic Cancer
- Initial 8 weeks: 1000 mg/m² IV over 30 minutes weekly × 7 weeks, followed by 1-week rest 1
- Maintenance: 1000 mg/m² IV on days 1,8, and 15 of each 28-day cycle 2
- Alternative: Fixed-dose rate at 10 mg/m²/minute (Category 2B) 2, 3
Non-Small Cell Lung Cancer (with cisplatin)
Two acceptable schedules:
- 28-day cycle: Gemcitabine 1000 mg/m² IV days 1,8,15 + cisplatin 100 mg/m² day 1 1
- 21-day cycle: Gemcitabine 1250 mg/m² IV days 1,8 + cisplatin 100 mg/m² day 1 1
The 21-day schedule achieves better dose compliance with fewer delays 4.
Metastatic Breast Cancer (with paclitaxel)
- Gemcitabine 1250 mg/m² IV days 1 and 8 of each 21-day cycle 1
- Paclitaxel 175 mg/m² as 3-hour infusion on day 1 before gemcitabine 1
Bladder Cancer (with cisplatin)
- Standard: Gemcitabine 1000 mg/m² IV days 1,8,15 + cisplatin 70 mg/m² day 2 every 28 days 4
- Alternative 21-day: Gemcitabine 1000 mg/m² days 1,8 + cisplatin 70 mg/m² day 1 or 2 5
The 3-week schedule demonstrates comparable efficacy with less hematologic toxicity and higher gemcitabine dose intensity 5.
Dose Modifications for Myelosuppression
Pancreatic Cancer & NSCLC (Day of Treatment)
| ANC (×10⁶/L) | Platelets (×10⁶/L) | Dose Modification |
|---|---|---|
| ≥1000 | ≥100,000 | Full dose |
| 500-999 | 50,000-99,999 | 75% of dose |
| <500 | <50,000 | Hold |
Breast Cancer
Day 1:
- ANC ≥1500 AND platelets ≥100,000: Full dose
- Below these thresholds: Hold
Day 8:
- ANC ≥1200 AND platelets >75,000: Full dose
- ANC 1000-1199 OR platelets 50,000-75,000: 75% dose
- ANC 700-999 AND platelets ≥50,000: 50% dose
- ANC <700 OR platelets <50,000: Hold
Monitoring Requirements
Baseline labs:
- Complete blood count with differential
- Comprehensive metabolic panel (renal and hepatic function)
- For cisplatin combinations: Calculate GFR to assess cisplatin eligibility 4
During treatment:
- CBC before each dose 2
- Renal and hepatic function periodically
- Monitor for pulmonary symptoms (dyspnea) 1
Common Adverse Effects
Hematologic (most common):
- Myelosuppression is dose-limiting 1, 6
- Neutropenia and thrombocytopenia occur frequently
- Grade 3-4 neutropenia more common with weekly cisplatin schedules 7
Non-hematologic:
- Flu-like symptoms (fever, chills, myalgias) 6, 8
- Nausea and vomiting (generally mild to moderate) 8
- Rash 6
- Transient transaminase elevations 1
- Peripheral edema (uncommon) 8
Rare but serious:
- Pulmonary toxicity (dyspnea, interstitial pneumonitis) 1
- Hemolytic uremic syndrome 1
- Severe cutaneous adverse reactions 1
- Capillary leak syndrome 1
- Posterior reversible encephalopathy syndrome 1
- Myositis (rare) 9
Permanent Discontinuation Required For:
- Severe cutaneous adverse reactions
- Unexplained dyspnea or severe pulmonary toxicity
- Hemolytic uremic syndrome or severe renal impairment
- Severe hepatic toxicity
- Capillary leak syndrome
- Posterior reversible encephalopathy syndrome
Critical Dosing Considerations
For patients with borderline renal function:
- Split-dose cisplatin (35 mg/m² days 1 and 2, or days 1 and 8) may be considered, though efficacy is undefined (Category 2B) 4
- Never substitute carboplatin for cisplatin in perioperative settings 4
Infusion rate matters: Fixed-dose rate (10 mg/m²/minute) maximizes intracellular phosphorylation and may improve survival compared to standard 30-minute infusion, though evidence is Category 2B 3.
No dose modifications needed for: Alopecia, nausea, or vomiting 1.
For other Grade 3-4 non-hematologic toxicity: Withhold or reduce dose by 50% until resolved 1.